Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results![Recent European legal developments on second medical uses and dosage regimes](/images/research/e8ad4951-ab08-446b-8ee8-5bb880c309f2/small/14685.jpg)
research Recent European legal developments on second medical uses and dosage regimes
European patent law now allows patents for new uses and dosages of known drugs, but protection scope is unclear.
![Generic competition and pharma patent strategies - a sequel](/images/research/ecca3ed2-36eb-4917-9dbf-7e1590fd5483/small/15050.jpg)
research Generic competition and pharma patent strategies - a sequel
The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
!['The Byzantine logic of patent law jurisprudence': patent protection for dosage regimes revisited](/images/research/c7cda792-7a14-401c-8a9e-3d7781969b01/small/14965.jpg)
research 'The Byzantine logic of patent law jurisprudence': patent protection for dosage regimes revisited
UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.
![Court of Appeal can overrule itself to follow the EPO: UK adopts EPO stance on second medical use claims](/images/research/2d722dda-0c78-4811-b923-1d2ead7734c8/small/15028.jpg)
research Court of Appeal can overrule itself to follow the EPO: UK adopts EPO stance on second medical use claims
The UK Court of Appeal ruled that new dosing regimens for drugs can be patented, aligning with the European Patent Office's approach.
![Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?](/images/research/8106fdec-be9f-435c-91bf-8f16fe4566c0/small/13815.jpg)
research Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?
The document suggests reevaluating the patent system to ensure public benefits from pharmaceutical privileges and to encourage more significant innovations.
Community Join
5 / 95 resultscommunity Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Dermatologist told me to quit fin after turning 40
A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.
community Hold up... CosmeRNA/SAMiRNA is actually coming real soon?
A user discovered CosmeRNA, a new hair loss treatment with clinical research backing, set to release soon. The conversation revolves around its potential effectiveness, cost, and how it compares to existing treatments like Minoxidil and Finasteride, with some users expressing hope for a side-effect-free option.
community 1 year fin 1mg and minox. can see some density reclaimed
User shared 1-year progress using finasteride 1mg and minoxidil, regaining hair density. Others praised the improvement and asked about side effects and additional treatments.
community 60-day progress with Minoxidil
A user shared a 60-day progress update on hair regrowth using only 5% Minoxidil foam once daily. Others suggested adding finasteride to address the underlying cause of hair loss and maintain long-term results.